<DOC>
	<DOCNO>NCT01296555</DOCNO>
	<brief_summary>This open-label , multicenter , Phase I/II study ass safety , tolerability , pharmacokinetics GDC-0032 . The Phase I portion divide two stage . During Stage 1 , GDC-0032 administer every day orally ( PO ) escalate dos participant locally advance metastatic solid tumor . During Stage 2 , GDC-0032 administer alone combination therapy within indication-specific cohort . In Phase II study , efficacy safety combination GDC-0032 fulvestrant evaluate post-menopausal female participant locally advance metastatic human epidermal growth factor receptor 2 ( HER2 ) -negative , hormone receptor-positive breast cancer .</brief_summary>
	<brief_title>A Dose Escalation Study Evaluating Safety Tolerability GDC-0032 Participants With Locally Advanced Metastatic Solid Tumors Non-Hodgkin 's Lymphoma ( NHL ) Combination With Endocrine Therapy Locally Advanced Metastatic Hormone Receptor-Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Phase I ( Cohorts A D , G , H , T , X ) : Histologically document , locally advanced metastatic solid malignancy NHL progress failed respond least one prior regimen candidate regimen know provide clinical benefit Phase I ( Cohorts E F ) : Postmenopausal females locally advanced metastatic hormone receptorpositive breast cancer progress failed respond least one prior endocrine therapy adjuvant metastatic set Phase I ( Cohorts J S ) : Postmenopausal female HER2negative , hormonereceptor positive breast cancer progress failed response least one prior endocrine therapy adjuvant metastatic setting Phase II : Postmenopausal female patient locally advance metastatic HER2negative , hormone receptorpositive breast cancer Phase I ( Cohorts A S ) Phase II : Evaluable measurable disease per Response Evaluation Criteria version 1.1 ( RECIST v1.1 ) Phase I ( Cohort T ) : Greater equal ( &gt; /= ) 1 bidimensionally measurable lesion compute tomography ( CT ) scan Phase I ( Cohort X ) : Measurable disease per RECIST v1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Screening Life expectancy &gt; /= 12 week Adequate hematologic organ function within 14 day prior initiation study treatment Documented willingness use effective mean contraception men woman participate study Known untreated , active central nervous system ( CNS ) metastases ( progress require treatment ) Active congestive heart failure ventricular arrhythmia require medication Participants require daily supplemental oxygen Active inflammatory disease require immunosuppressant , include small large intestinal inflammation Crohn 's disease ulcerative colitis Clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Treatment chemotherapy less equal ( &lt; /= ) 3 week study treatment Oral endocrine therapy &lt; /= 2 week study treatment Treatment investigational drug &lt; /= 3 week 5 halflives study treatment Treatment biologic therapy &lt; /= 3 week study treatment Treatment kinase inhibitor &lt; /= 2 week study treatment Radiation therapy ( radiation bony metastasis ) cancer therapy &lt; /= 4 week study treatment Palliative radiation therapy bony metastasis &lt; /= 2 week study treatment Major surgery &lt; /= 4 week study treatment Any disease , active uncontrolled pulmonary dysfunction , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug , may affect interpretation result , render participant high risk treatment complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>